Edgewise Therapeutics (EWTX) Assets (2020 - 2026)
Edgewise Therapeutics (EWTX) posted Assets of $518.5 million for Q1 2026, down 6.17% sequentially from $552.6 million in Q4 2025, and up 14.11% YoY from $454.4 million in Q1 2025.
Edgewise Therapeutics (EWTX) Assets (2020 - 2026) Analysis & Trends
Edgewise Therapeutics has reported Assets for 7 years, with the latest figure at $518.5 million in Q1 2026.
- Quarterly Assets rose 14.11% year-over-year to $518.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $518.5 million (up 14.11% YoY) and the FY2025 annual result came in at $552.6 million, up 13.51% from the prior year.
- Assets slipped to $518.5 million in Q1 2026 per EWTX's latest filing, from $552.6 million in the prior quarter.
- Over five years, Assets peaked at $613.3 million in Q2 2025 and troughed at $257.4 million in Q2 2022.
- A 5-year average of $435.8 million and a median of $454.4 million in 2025 frame the typical range for Assets.
- The sharpest annual moves came in 2024 and 2025: Assets jumped 64.21% in 2024, then retreated 17.95% in 2025.
- Over 5 years, Assets stood at $367.1 million in 2022, then decreased by 7.37% to $340.0 million in 2023, then soared by 43.17% to $486.8 million in 2024, then grew by 13.51% to $552.6 million in 2025, then declined by 6.17% to $518.5 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $518.5 million, $552.6 million, and $583.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Edgewise Therapeutics | 4.76 Bn | 4.76 Bn | - | 479.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 479.69 Mn |
| Mar 31, 2026 | 518.52 Mn |
| Dec 31, 2025 | 552.60 Mn |
| Sep 30, 2025 | 583.47 Mn |
| Jun 30, 2025 | 613.33 Mn |
| Mar 31, 2025 | 454.39 Mn |
| Dec 31, 2024 | 486.82 Mn |
| Sep 30, 2024 | 511.28 Mn |
| Jun 30, 2024 | 531.65 Mn |
| Mar 31, 2024 | 553.81 Mn |
| Dec 31, 2023 | 340.04 Mn |
| Sep 30, 2023 | 311.36 Mn |
| Jun 30, 2023 | 330.63 Mn |
| Mar 31, 2023 | 346.40 Mn |
| Dec 31, 2022 | 367.10 Mn |
| Sep 30, 2022 | 377.15 Mn |
| Jun 30, 2022 | 257.40 Mn |
| Mar 31, 2022 | 272.75 Mn |
| Dec 31, 2021 | 285.23 Mn |
| Sep 30, 2021 | 294.45 Mn |